Abstract
Immune checkpoint inhibitor-related myasthenia gravis and its overlap syndrome with myocarditis and myositis occur early after initiation of therapy and are associated with significant mortality. 1, 2 The clinical course of immune checkpoint inhibitor-mediated myasthenia gravis tends to be more aggressive than its de novo counterparts and management strategies must be adapted to recognize this. We describe a presentation of this condition, which may offer further insights into its disease course and management.